Product logins

Find logins to all Clarivate products below.


Varicose Vein Treatment Devices – Market Insights – Europe (Supplemental)

Although the COVID-19 global pandemic has negatively impacted the European varicose vein treatment device market in the short term, the market has largely recovered and will grow moderately over the remainder of the forecast period, supported by a shift toward and a changing reimbursement landscape for endovenous ablation technologies, namely ERFA and ELA, which will compete with surgical stripping procedures.

This Medtech 360 Report provides high-level market metrics for varicose vein treatment device market in Europe, including country-level data for major countries and aggregate data for the rest of the Europe from 2019 through 2031.

Table of contents


Related Medtech Insights Reports

Report
Cardiac Rhythm Management Devices – Market Insights – United States
The US CRM device market is projected to grow slightly through 2035, driven by the increasing adoption of innovative devices, particularly extravascular ICDs, and CSP-capable pacing and…
Report
Deep Venous Disease Treatment Devices – Market Insights – Global
The uptake of innovative, higher-priced powered thrombectomy devices and their increasing adoption for treating PE—supported by favorable clinical data—will drive strong growth in the global…
Report
Neurovascular Devices – Market Insights – Asia Pacific
The Asia Pacific neurovascular device market will grow moderately through the forecast period, driven by rising procedure volumes, anticipated product launches, and increasing affordability of…
Report
Cardiac Rhythm Management Devices – Market Insights – Asia Pacific
The Asia Pacific CRM device market will register modest growth over the forecast period. Key growth drivers include the rising adoption of premium-priced technologies such as CRT devices, leadless…
Report
Electrophysiology Mapping and Ablation Devices – Market Insights – Europe
The European EP mapping and ablation device market will grow moderately through 2035, driven by the rising prevalence of cardiac arrhythmias, improved access to treatment, advancements in ablation…